Navamedic ASA : Approved Prospectus
(Thomson Reuters ONE) -
Reference is made to the stock exchange announcement from Navamedic ASA (the
"Company") published on 13 June 2016 regarding the strategic partnership and 8-
year distribution agreement with TopRidge Pharma Limited and the stock exchange
announcement published 17 June 2016 regarding the registration of share capital
increase.
The Norwegian Financial Supervisory Authority (Nw. Finanstilsynet) has on 1
November 2016 approved a prospectus prepared by the Company for the listing of
1,417,522 new shares in the Company, each with a nominal value of NOK 1. The new
shares, having been registered on a separate ISIN and not been tradable on the
Oslo Stock Exchange since its issuance, will following the publication of the
prospectus be transferred to the Company's ordinary ISIN and be tradable on the
Oslo Stock Exchange. TopRidge has agreed on a lock-up period of 12 months,
following the completion date of the investment. In this period the newly issued
shares shall not be sold. The prospectus is attached to this stock exchange
notice and will also be made available at the Company's website,
www.navamedic.com. Printed copies of the prospectus may be obtained free of
charge at the offices of the Company in Bærum, Norway.
For further information, please contact Toril Marie Ås, CFO Navamedic ASA,
toril.as(at)navamedic.com, Tel: +47 95 70 10 71.
Navamedic ASA, Bærum, 1 November 2016
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
Prospectus:
http://hugin.info/136020/R/2053262/768494.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Navamedic ASA via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 01.11.2016 - 12:10 Uhr
Sprache: Deutsch
News-ID 504148
Anzahl Zeichen: 2220
contact information:
Town:
Lysaker
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 159 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Navamedic ASA : Approved Prospectus"
steht unter der journalistisch-redaktionellen Verantwortung von
Navamedic ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
